Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 20:1. Implied volatility suggests the market is anticipating a move near 10.6%, or 80c, after results are released. Median move over the past eight quarters is 8.8%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics appoints Binks as Chief Medical Officer
- Capricor Therapeutics, Inc. (CAPR) Q1 Earnings Cheat Sheet
- Capricor FDA panel meeting ‘not unexpected,’ says JonesResearch
- Capricor share weakness unwarranted, says H.C. Wainwright
- Capricor completes mid-cycle review with FDA for BLA for deramiocel